SH3TC2: A Potential Drug Target for Various Diseases (G255187)

Target Name: SH3TC2-DT

NCBI ID: G255187

SH3TC2-DT

Other Name(s): SH3TC2 divergent transcript

SH3TC2: A Potential Drug Target for Various Diseases

SH3TC2-DT, also known as SH3TC2-derived transcript, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. SH3TC2 is a non-coding RNA molecule that has been shown to play a role in regulating gene expression and has been linked to the development and progression of various diseases.

The SH3TC2 gene was identified through a combination of computational and biochemical approaches. The SH3TC2 gene was identified by using RNA-seq technology to analyze transcriptome data from various organisms, including human, mouse, and fish. The gene was then confirmed by bioinformatics analysis and through in vitro and in vivo experiments.

SH3TC2 has been shown to play a role in the regulation of gene expression in various organisms, including humans. Studies have shown that SH3TC2 can interact with various transcription factors, including nuclear factor E2F1, to regulate gene expression. This interaction between SH3TC2 and E2F1 has been shown to play a role in the regulation of cell growth, differentiation, and survival.

In addition to its role in gene regulation, SH3TC2 has also been shown to be involved in the development and progression of various diseases. Studies have shown that SH3TC2 is highly expressed in various cancer tissues and that it has been associated with the development of various types of cancer, including breast, ovarian, and prostate cancer. Additionally, SH3TC2 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

The potential drug target or biomarker properties of SH3TC2 have led to its potential as a therapeutic target for various diseases. Studies have shown that SH3TC2 can be effectively targeted with small molecules, including inhibitors of the SH3TC2-E2F1 interaction. Additionally, SH3TC2 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This suggests that SH3TC2 may be a useful biomarker for the diagnosis and treatment of diseases associated with TGF-β signaling pathway dysfunction.

In conclusion, SH3TC2 is a non-coding RNA molecule that has been shown to play a role in regulating gene expression and has been linked to the development and progression of various diseases. Its potential as a drug target or biomarker has led to its investigation as a potential therapeutic agent for a variety of diseases. Further research is needed to fully understand the role of SH3TC2 in disease progression and to develop effective treatments.

Protein Name: SH3TC2 Divergent Transcript

The "SH3TC2-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3TC2-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets